Literature DB >> 2592775

Thymic involution and thymocyte phenotypic alterations induced by murine mammary adenocarcinomas.

Y Fu1, R D Paul, Y Wang, D M Lopez.   

Abstract

A profound thymic atrophy has been observed in mice bearing large adenocarcinomas of the mammary gland. Only 2 to 5% of thymocytes remained 4 wk after tumor implantation. Although there is a slight decrease in the overall percentages of Thy-1+ cells in tumor bearers, the majority of the remaining cells are of a Thy-1 low phenotype. There was a lower percentage of double positive (CD4+, CD8+) cells, an increase of CD4+ CD8- thymocytes, similar percentages of CD4- CD8+ cells and double negative (CD4- CD8-) thymocytes in tumor-bearing mice. In addition, an increased percentage of CD3 cells could be detected in these animals. These results indicate that proportionally less immature thymocytes are present in the atrophic thymuses of mammary tumor bearers. Enhanced levels of glucocorticoids are known to produce similar effects on the thymus. However, adrenalectomy of mice followed by tumor implantation did not result in reversal of the thymic atrophy. Furthermore, a study of serum corticosterone levels in tumor bearers indicated no significant changes during tumorigenesis. A study of several parameters of bone marrow (BM) populations indicate that there is an increase in cells of the granulocyte-macrophage lineage and a decrease in lymphocytes induced by tumor-derived granulocyte macrophage-CSF. An alteration of prothymocytes in the BM is not the main cause of the thymic atrophy because BM cells from normal and tumor-bearing mice reconstituted irradiated normal mice equally well. There was no preferential recruitment of double positive cells to the spleen as indicated by no significant differences in the levels of T cells of immature phenotype including the CD4+ CD8+ population in the spleens of tumor bearers. Because no major changes were observed in tumor bearers, either at their capacity to repopulate the thymus or at the patterns of subsequent redistribution of thymocytes, it was postulated that the thymic atrophy may be caused by a direct or indirect effect of the tumor or tumor-associated factor(s). Intrathymic injections of tumor cells into young normal recipient mice resulted in a significant reduction of the thymus weight and cellularity. These data suggest that mammary tumors can secrete factor(s) that are capable of severely impairing the normal development of cells of the T cell lineage.

Entities:  

Mesh:

Year:  1989        PMID: 2592775

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

Review 1.  Influence of breast cancer on thymic function in mice.

Authors:  Diana M Lopez; Vijaya Charyulu; Becky Adkins
Journal:  J Mammary Gland Biol Neoplasia       Date:  2002-04       Impact factor: 2.673

2.  Lymphotoxin activates hepatic T cells and simultaneously induces profound thymic atrophy.

Authors:  A Kusumi; T Abo; T Masuda; K Sugiura; S Seki; T Ohteki; R Okuyama; K Kumagai
Journal:  Immunology       Date:  1992-10       Impact factor: 7.397

Review 3.  Insights into thymic involution in tumor-bearing mice.

Authors:  Roberto Carrio; Diana M Lopez
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

4.  SJSZ glycoprotein (38 kDa) modulates expression of IL-2, IL-12, and IFN-γ in cyclophosphamide-induced Balb/c.

Authors:  Jin Lee; Kye-Taek Lim
Journal:  Inflamm Res       Date:  2012-07-20       Impact factor: 4.575

5.  In vivo induction of apoptosis in the thymus by administration of mycobacterial cord factor (trehalose 6,6'-dimycolate).

Authors:  Y Ozeki; K Kaneda; N Fujiwara; M Morimoto; S Oka; I Yano
Journal:  Infect Immun       Date:  1997-05       Impact factor: 3.441

6.  The thymic epithelial microRNA network elevates the threshold for infection-associated thymic involution via miR-29a mediated suppression of the IFN-α receptor.

Authors:  Aikaterini S Papadopoulou; James Dooley; Michelle A Linterman; Wim Pierson; Olga Ucar; Bruno Kyewski; Saulius Zuklys; Georg A Hollander; Patrick Matthys; Daniel H D Gray; Bart De Strooper; Adrian Liston
Journal:  Nat Immunol       Date:  2011-12-18       Impact factor: 25.606

7.  The immune system response during development and progression of carcinogen-induced rat mammary tumors: prevention of tumor growth and restoration of immune system responsiveness by thymopentin.

Authors:  F Gallo; M C Morale; D Sambataro; Z Farinella; U Scapagnini; B Marchetti
Journal:  Breast Cancer Res Treat       Date:  1993-09       Impact factor: 4.872

8.  Thymic function and output of recent thymic emigrant T cells during intracranial glioma progression.

Authors:  Robert M Prins; Martin R Graf; Randall E Merchant; Keith L Black; Christopher J Wheeler
Journal:  J Neurooncol       Date:  2003 Aug-Sep       Impact factor: 4.130

9.  MHC class I antigens and tumour-infiltrating leucocytes in laryngeal cancer: long-term follow-up.

Authors:  F Esteban; M Redondo; M Delgado; F Garrido; F Ruiz-Cabello
Journal:  Br J Cancer       Date:  1996-12       Impact factor: 7.640

10.  Oncolytic adenovirus coexpressing interleukin-12 and shVEGF restores antitumor immune function and enhances antitumor efficacy.

Authors:  Hyo Min Ahn; JinWoo Hong; Chae-Ok Yun
Journal:  Oncotarget       Date:  2016-12-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.